Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cells.
We show that absolute and severe neutropenia after high-dose therapy with melphalan with or without total body irradiation can be abrogated by cells generated ex vivo. This may change the clinical practice of haematopoietic cell transplantation and high-dose chemotherapy because the morbidity and hospitalisation associated with neutropenia could be avoided or reduced.
Reiffers
J
J
Cailliot
C
C
Dazey
B
B
Attal
M
M
Caraux
J
J
Boiron
J M
JM
D000328:Adult; D018952:Antigens, CD34 / Q000008:administration & dosage* / Q000097:blood / Q000302:isolation & purification; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D002478:Cells, Cultured; D003131:Combined Modality Therapy; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008558:Melphalan / Q000009:adverse effects*; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000532:radiotherapy; D009503:Neutropenia / Q000139:chemically induced* / Q000628:therapy*
D018952:Antigens, CD34; D018906:Antineoplastic Agents, Alkylating; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D008558:Melphalan